제닉
Financials
Valuation Metrics
제닉's Market Cap is ₩1905B. At end of 2025 it was ₩1316B. Ranked #850 of 2,436 in KR market (top 35%), #392 of 1,649 on KOSDAQ (top 24%), #23 of 57 in Household & Personal Products (top 40%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 190.45B KRW | KR#850/2,436 Sec#23/57 |
| Revenue | 89.73B KRW | KR#1,461/2,436 Sec#32/57 |
| Net Income | 18.85B KRW | KR#669/2,436 Sec#16/57 |
| Total Assets | 66.90B KRW | KR#2,015/2,436 Sec#43/57 |
| Net Assets | 44.56B KRW | KR#1,953/2,436 Sec#42/57 |
| Employees | 356 | KR#681/2,436 Sec#14/57 |
| Value | ||
| P/E | 10.11x | KR#722/2,436 Sec#13/57 |
| P/B | 4.27x | KR#2,214/2,436 Sec#52/57 |
| P/S | 2.12x | KR#1,858/2,436 Sec#46/57 |
| EV/EBITDA | 12.81x | KR#762/2,436 Sec#19/57 |
| FCF Yield | 9.44% | KR#645/2,436 Sec#10/57 |
| Profitability | ||
| ROE | 42.30% | KR#12/2,436 Sec#2/57 |
| ROA | 28.17% | KR#12/2,436 Sec#3/57 |
| Op. Margin | 16.30% | KR#237/2,436 Sec#5/57 |
| Revenue Growth | 64.66% | KR#220/2,436 Sec#2/57 |
| Earnings Growth | -1.13% | KR#907/2,436 Sec#25/57 |
| Financial Health | ||
| Debt Ratio | 150.14% | KR#1,186/2,436 Sec#34/57 |
| Total Debt | 2.21B KRW | KR#1,884/2,436 Sec#45/57 |
| FCF | 17.98B KRW | KR#545/2,436 Sec#13/57 |
| Cash | 5.34B KRW | KR#1,963/2,436 Sec#47/57 |
| Current Ratio | 1.95x | KR#977/2,436 Sec#28/57 |
| Net Debt/EBITDA | -0.21x | KR#646/2,436 Sec#21/57 |
| Performance | ||
| 1Y Return | -31.91% | KR#1,613/2,436 Sec#32/57 |
| 1M Return | -7.18% | KR#1,575/2,436 Sec#46/57 |
| From 52W High | -41.99% | KR#850/2,436 Sec#29/57 |
| 1Y MDD | -62.63% | KR#1,563/2,436 Sec#39/57 |
| Trading | ||
| Volume | 209,877 shares | KR#551/2,436 Sec#9/57 |
| Foreign Own. | 1.63% | KR—/2,436 Sec—/57 |
| Per Share | ||
| EPS | 2,365 KRW | KR#348/2,436 Sec#8/57 |
| BPS | 5,694 KRW | KR#1,349/2,436 Sec#29/57 |
Company Info
Established in 2001 for the research, development, manufacturing, and sale of cosmetics and pharmaceuticals, the company was listed on KOSDAQ in 2011 and owns a wholly-owned sales corporation in China. Its core business revolves around R&D, manufacturing, and sales, leveraging its globally patented hydrogel technology. The company's brands are distributed through diverse channels, with online sales boosted by social media and influencer marketing. Increased product development and production requests reflect the acquisition of CGMP and various international certifications. Genic is headquartered in Seongnam-si, Gyeonggi-do.